# A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

> **NCT04849715** · PHASE3 · WITHDRAWN · sponsor: **Incyte Corporation**

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** parsaclisib
- **DRUG:** rituximab
- **DRUG:** bendamustine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04849715
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-11
- **Primary completion:** 2030-08-15
- **Final completion:** 2034-07-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** business decision; no enrolled patients
- **Last updated:** 2022-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849715, "A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04849715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*